Update: Facial Filler Use Now Reported by Moderna COVID-19 Vaccine Trial Participants
Moderna mRNA-1273-P301 study participants will now be asked to disclose information about their use of facial fillers.
All articles by Heidi W. Moore
Facial Fillers and the COVID-19 Vaccine
The American Society for Dermatologic Surgery (ASDS) has released a new guidance regarding adverse events associated with the SARS-CoV-2 mRNA vaccine and dermal fillers.
Anifrolumab May Reduce Skin Disease Severity in Patients With Active Systemic Lupus Erythematosus
Researchers evaluated the effect on skin-specific systemic lupus erythematosus disease activity using data pooled from the TULIP-1 and TULIP-2 trials.
Is It COVID-19 or Is It Your Meds?
Taste and smell disturbances are common symptoms of COVID-19, but they can also be caused by medications frequently prescribed by dermatologists.
Do TNFis Reduce the Risk for Progression to PsA in Patients With Psoriasis?
Researchers evaluated the use of TNFis vs methotrexate in reducing the risk for progression to psoriatic arthritis in patients with psoriasis.
COVID Toes: Dermatologic Observations and Theories
Observations and theories about the emergence of “COVID toes” in patients are discussed with Adam Friedman, MD, FAAD.
Registries Established for Patients With Psoriasis, Atopic Dermatitis, and COVID-19
New registries have been established to capture emerging data on patients with psoriasis and atopic dermatitis who have COVID-19.
Biologic, Immunosuppressive Therapies Not Tied to Severe Outcomes From COVID-19 Infection
A study from Italy reports severe outcomes related to the COVID-19 infection in patients with chronic plaque psoriasis receiving immunosuppressive therapies.
Managing Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa During COVID-19
The outbreak of COVID-19 affects the management of chronic dermatologic disease in those patients already receiving therapy and patients about to begin a new treatment.
Management of Systemic Immunomodulators During the COVID-19 Pandemic
An understanding of pathophysiology may serve to guide clinical decision making when using biologic agents during the COVID-19 pandemic.
-
Loading...
-
Loading...
Next post in General Dermatology
